TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development

Tools

Kaufmann, Stefan H. E. and Dockrell, Hazel M. and Drager, Nick and Ho, Mei Mei and McShane, Helen and Neyrolles, Olivier and Ottenhoff, Tom H. M. and Patel, Brij and Roordink, Danielle and Spertini, François and Stenger, Steffen and Thole, Jelle and Verreck, Frank A. W. and Williams, Ann and Britton, Warwick and Triccas, Jamie and Counoupas, Claudio and Grooten, Johan and Marie-Ange Demoitie, Demoitie and Romano, Marta and Huygen, Kris and Tima, Hermann Giresse and Mascart, Francoise and Andersen, Peter and Aagaard, Claus and Christensen, Dennis and Ruhwald, Morten and Lindenstrom, Thomas and Charneau, Pierre and Guilhot, Christophe and Peixoto, Antonio and Gilleron, Martine and Vergne, Isabelle and Locht, Camille and Brosch, Roland and Inchauspe, Genevieve and Theung Long, Stephane Leung and Weiner, January and Maertzdorf, Jeroen and Nieuwenhuizen, Natalie and Bastian, Max and Kallert, Stephanie and Gordon, Stephen and Caccamo, Nadia and Goletti, Delia and Nisini, Roberto and Shin, Sung Jae and Cho, Sang Nae and Lee, Hyejon and Perrie, Yvonne, TBVAC2020 Consortium (2017) TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development. Frontiers in Immunology, 8 (OCT). pp. 1-18. 1203. ISSN 1664-3224 (https://doi.org/10.3389/fimmu.2017.01203)

[thumbnail of Kaufmann-etal-FI2017-TBVAC2020-advancing-tuberculosis-vaccines-from-discovery]
Preview
 Text. Filename: Kaufmann_etal_FI2017_TBVAC2020_advancing_tuberculosis_vaccines_from_discovery.pdf
Final Published Version
Download (1MB)| Preview

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

CORE (COnnecting REpositories)